The left ventricular dysfunction (LVD), from asymptomatic reduction of left ventricular ejection fraction (LVEF) up to heart failure (HF), is probably the most studied and feared late effect of anticancer therapy because it is often unpredictable and because it has a poor prognosis. It may result from many anticancer drugs through different mechanisms and often for a different combination of cardiotoxic effects in a polychemotherapy schedule.